Sachiyo Yoshio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1370284/publications.pdf

Version: 2024-02-01

47	1,052	489802	511568
papers	citations	18 h-index	30 g-index

50	50	50	2037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sphingosineâ€1â€phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy. Hepatology, 2022, 76, 112-125.	3.6	22
2	Effects of <scp>SGLT2</scp> inhibitor on tumorâ€releasing chemokines/cytokines in <scp>Hep3B</scp> and <scp>Huh7</scp> cells. JGH Open, 2022, 6, 270-273.	0.7	0
3	Metabolic dysfunctionâ€associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients. Hepatology Research, 2022, 52, 841-858.	1.8	7
4	Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. Journal of Infectious Diseases, 2021, 223, 2080-2089.	1.9	13
5	Pharmacotherapy options for managing hepatitis B in children. Expert Opinion on Pharmacotherapy, 2021, 22, 449-467.	0.9	3
6	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. Cancers, 2021, 13, 194.	1.7	15
7	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. BMC Gastroenterology, 2021, 21, 55.	0.8	6
8	Increased Frequency of Dysfunctional Siglec-7â^'CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. Frontiers in Immunology, 2021, 12, 603133.	2.2	13
9	Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy. Hepatology Communications, 2021, 5, 1437-1447.	2.0	16
10	Myostatin as a fibroblastâ€activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. Hepatology Research, 2021, 51, 803-812.	1.8	18
11	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	6
12	Effects of a lowâ€intensity resistance exercise program on serum miRâ€630, miRâ€5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study. Hepatology Research, 2021, 51, 823-833.	1.8	11
13	Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma. Cells, 2021, 10, 1495.	1.8	7
14	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunological Medicine, 2021, 44, 175-186.	1.4	5
15	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. Viruses, 2021, 13, 2101.	1.5	8
16	Metabolic dysfunctionâ€associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?. Hepatology Research, 2021, 51, 1097-1099.	1.8	0
17	Serum soluble sialic acidâ€binding immunoglobulinâ€like lectinâ€7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2020, 50, 466-477.	1.8	7
18	Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis. Immunity, 2020, 52, 542-556.e13.	6.6	33

#	Article	IF	Citations
19	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 936.	1.0	13
20	High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C. JPGN Reports, 2020, 1, e005.	0.2	1
21	Increased frequency of PD-1+CD57+Siglec-7- dysfunctional NK cells in patients with nonalcoholic fatty liver disease.. Journal of Clinical Oncology, 2020, 38, 589-589.	0.8	0
22	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Global Health & Medicine, 2020, 2, 273-281.	0.6	4
23	Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Scientific Reports, 2019, 9, 15788.	1.6	20
24	Liver disease secondary to congenital heart disease in children. Expert Review of Gastroenterology and Hepatology, 2019, 13, 651-666.	1.4	22
25	Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After Firstâ€Time Hepatitis B Vaccination. Hepatology Communications, 2019, 3, 812-824.	2.0	8
26	High serum interleukinâ€34 level is a predictor of poor prognosis in patients with nonâ€viral hepatocellular carcinoma. Hepatology Research, 2019, 49, 1046-1053.	1.8	21
27	Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. Journal of Gastroenterology, 2019, 54, 1007-1018.	2.3	29
28	USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation. Journal of Virology, 2019, 93, .	1.5	17
29	Tumor necrosis factorâ€Î±â€mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. Hepatology Communications, 2018, 2, 407-420.	2.0	27
30	MicroRNAâ€125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. Hepatology Research, 2018, 48, 313-321.	1.8	25
31	Infection with flaviviruses requires BCLXL for cell survival. PLoS Pathogens, 2018, 14, e1007299.	2.1	28
32	Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon-Î² from Human Dendritic Cells. Frontiers in Immunology, 2018, 9, 27.	2.2	22
33	Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI Insight, 2018, 3, .	2.3	32
34	Proâ€angiogenic TIEâ€2â€expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. International Journal of Cancer, 2017, 141, 1011-1017.	2.3	5
35	Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease. Euroasian Journal of Hepato-gastroenterology, 2017, 7, 60-64.	0.1	8
36	Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10388-10393.	3.3	76

#	Article	IF	Citations
37	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 35282.	1.6	77
38	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Scientific Reports, 2016, 6, 28814.	1.6	47
39	Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx. Journal of Virology, 2016, 90, 3530-3542.	1.5	27
40	Indoleamineâ€2,3â€dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology, 2016, 63, 83-94.	3.6	38
41	Hostâ€“virus interactions in hepatitis B and hepatitis C infection. Journal of Gastroenterology, 2016, 51, 409-420.	2.3	23
42	Association of serum IFN-Î»3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. Journal of Gastroenterology, 2015, 50, 894-902.	2.3	30
43	Abstract 569: Comprehensive analyses of serum biomarkers associating with the increase of pro-angiogenic Tie2-expressing monocytes in patients with hepatocellular carcinoma. , 2015, , .		0
44	Ex vivo induction of IFN-Î»3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients. Journal of Gastroenterology, 2014, 49, 126-137.	2.3	19
45	Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. Journal of Gastroenterology, 2013, 48, 660-670.	2.3	41
46	TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology, 2013, 57, 1416-1425.	3.6	115
47	Human blood dendritic cell antigen 3 (BDCA3)⁺dendritic cells are a potent producer of interferon-Î» in response to hepatitis C virus. Hepatology, 2013, 57, 1705-1715.	3.6	86